AstraZeneca, working to grow Fasenra’s reach, touts positive trial against GSK's...

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Sep 12, 2023 at 07:22: PM
via Competing to treat patients with severe eosinophilic asthma (SEA), AstraZeneca has fared well matching its IL-5 inhibitor Fasenra up against GSK’s Nucala.

article source
 

<



Similar threads

cafead
Alphabet&#039;s quantum spinoff starts working with AstraZeneca, Sanofi to accelerate R&amp;D
Replies
0
Views
328
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca, Daiichi Sankyo working on Japanese supply deal for COVID-19 vaccine hopeful
Replies
0
Views
137
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca’s Imfinzi and Imjudo found to extend survival in liver cancer trial
Replies
0
Views
20
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
AstraZeneca steps out from Daiichi&#039;s shadow, posting data on in-house rivals to AbbVie and Pfizer ADCs
Replies
0
Views
12
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
ESMO: AstraZeneca&#039;s Imfinzi extends life in bladder cancer type. Will FDA push back on its perioperative trial design?
Replies
0
Views
22
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote